OVARIAN CANCER and US: chemobrain

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Showing posts with label chemobrain. Show all posts
Showing posts with label chemobrain. Show all posts

Saturday, May 05, 2012

Structural and Functional Imaging and Cognitive Functions in Ovarian Cancer - Full Text View - ClinicalTrials.gov (clinical trials)



Structural and Functional Imaging and Cognitive Functions in Ovarian Cancer - Full Text View - ClinicalTrials.gov

This study is currently recruiting participants.
Verified May 2012 by Memorial Sloan-Kettering Cancer Center

First Received on April 30, 2012.   Last Updated on May 2, 2012   History of Changes
Sponsor: Memorial Sloan-Kettering Cancer Center
Collaborator: Weill Medical College of Cornell University
Information provided by (Responsible Party): Memorial Sloan-Kettering Cancer Center ( Memorial Sloan-Kettering Cancer Center )
ClinicalTrials.gov Identifier: NCT01591772
  Purpose
The purpose of this study is to learn about possible changes in brain anatomy and function, and in thinking abilities, such as memory skills, in patients with ovarian cancer who receive treatment with chemotherapy. Cancer patients treated with chemotherapy may experience changes in thinking abilities, and these may interfere with quality of life. Most of the research to date has involved patients with breast cancer, and there are no studies in women with ovarian cancer looking at at treatment-related changes in brain anatomy and function.

Saturday, April 28, 2012

Rivkin Center (Seattle) awards grant for cognitive study (ovarian cancer/chemobrain)



 Blogger's Note: many ovarian cancer survivors who have gone before us would be happy with this news (Shirley Inveen, Sheryl Eisenbarth.....)

Rivkin Center awards grant for cognitive study:

CONGRATULATIONS DR. GRAY!

Heidi Gray, MD

University of Washington


Behavioral and neural indices of cognitive rehabilitation in ovarian cancer
Millions of ovarian cancer survivors live with residual symptoms of impaired thinking and impaired memory severe enough to interfere with basic activities of daily living and work. However, very little is known about how to treat problems in cognition. Pharmacologic interventions have only been modestly helpful, if at all, and not all patients desire or are able to take medications. Dr. Gray will examine the ability of a 7-week cognitive rehabilitation intervention to improve memory and thinking abilities in ovarian cancer survivors. In addition, the project will measure changes in brain activity patterns from the treatment using neuroimaging.

Marsha Rivkin Center for Ovarian Cancer Research | supporting research in honor of our wives, mothers, sisters, and daughters
The Rivkin Center is delighted to announce the recipients of its 2012 Scientific Grants.

Monday, April 02, 2012

open access: Impaired Cognitive Function and Hippocampal Neurogenesis following Cancer Chemotherapy (Chemobrain)



 Blogger's Note: also refer to previous post regarding chemobrain research in mice, differences in the 2 studies include chemotherapy agents, but, same bottom line results (confirmation of side effects/adverse effects of chemotherapy treatments)

Impaired Cognitive Function and Hippocampal Neurogenesis following Cancer Chemotherapy


Conclusions (abstract): 
Our results show that chronic treatment with either of two commonly used chemotherapeutic agents impairs cognitive ability and suggest that strategies to prevent or repair disrupted hippocampal neurogenesis may be effective in ameliorating this serious side effect in cancer survivors.

open access: The Effects of Chemotherapy on Cognitive Function in a Mouse Model: A Prospective Study (Chemobrain)



Blogger's Note:  note article for observations regarding duration of chemobrain/MRI imaging

The Effects of Chemotherapy on Cognitive Function in a Mouse Model: A Prospective Study


Monday, February 27, 2012

JCO: Neuropsychological Performance in Survivors of Breast Cancer More Than 20 Years After Adjuvant Chemotherapy (chemobrain)



Breast Cancer Neuropsychological Performance in Survivors of Breast Cancer More Than 20 Years After Adjuvant Chemotherapy
JCO published online on February 27, 2012; DOI:10.1200/JCO.2011.37.0189.

Thursday, February 16, 2012

abstract: Cognitive function and quality of life in ovarian cancer- Gynecologic Oncology (chemobrain)



Objectives

As advances in treatment have prolonged survival for many patients with ovarian cancer, there has been growing interest in assessing the adverse effects of disease and treatment. The aim of this study was to review the literature on cognitive function and quality of life (QOL) in this population.

Results

The small number of studies including formal evaluations of neurocognitive function suggests that many ovarian cancer patients experience cognitive difficulties associated with their disease and treatment. Several studies described declines in self-reported cognitive function that may impact QOL, but the results were not consistent across studies.

Highlights

► The literature suggests that many patients with ovarian cancer experience cognitive difficulties associated with their disease and treatment.
► Several studies reported declines in self-reported cognitive function that may impact QOL, but the results were inconsistent across studies.

Wednesday, February 08, 2012

open access: “Doctor, Will the Treatment You Are Recommending Cause Chemobrain?” JCO



Blogger's Note: actually it has been closer to 2 decades (or more); most of the prior research focused on breast cancer patients as is the case with the references in this article

     ~~~~~~~~~~~~~~~~~

"For more than a decade, patients and their oncologists have been sharing conversations about cognitive complaints after chemotherapy treatment.1 Early on, only occasional patients complained of trouble with concentration and memory during treatment, with a minority noting persistence beyond the end of treatment. The oncologist, who rarely heard this complaint, could be dismissive, saying that the drugs the patient received did not cross the blood-brain barrier, and therefore, it was unlikely that the difficulties were related to the cancer treatment. Post-treatment cognitive complaints became much more evident during the late 1990s and early 21st century as adjuvant treatment regimens intensified and autologous bone marrow transplantation became more common in adults.2,3 ......."

"In summary, patient complaints of persistent cognitive difficulties after cancer treatment ends must not be dismissed, given that there is mounting evidence for the biologic effects of cancer treatments on behavioral symptoms, and cognitive complaints are one of the most troublesome of these manifestations.21,40,41..."......We can no longer deny the existence of this long-term effect of cancer treatment; we must work to tailor future treatments to minimize this adverse outcome."

Thursday, January 19, 2012

abstract: Prevalence of Self-Reported Memory Problems in Adult Cancer Survivors: A National Cross-Sectional Study



Conclusion:
Cancer history independently predicted SRM impairment. Prevalence of SRM (self-reported memory) impairment in people with a history of cancer/cancer treatment is substantial and increasing. Health care providers should assess and be ready to treat memory impairment in patients with a history of cancer.

abstract: Longitudinal Assessment of Chemotherapy-Induced Structural Changes in Cerebral White Matter and Its Correlation With Impaired Cognitive Functioning



Conclusion
We report evidence of longitudinal changes in cognitive functioning and cerebral WM (white matter) integrity after chemotherapy as well as an association between both.

open access: JCO - “Doctor, Will the Treatment You Are Recommending Cause Chemobrain?”



"For more than a decade, patients and their oncologists have been sharing conversations about cognitive complaints after chemotherapy treatment.1 Early on, only occasional patients complained of trouble with concentration and memory during treatment, with a minority noting persistence beyond the end of treatment. The oncologist, who rarely heard this complaint, could be dismissive, saying that the drugs the patient received did not cross the blood-brain barrier, and therefore, it was unlikely that the difficulties were related to the cancer treatment........."

Wednesday, April 20, 2011

Spring 2011 Cure Magazine/website - "Take Our Poll' - chemobrain



Note: see very top of website page and click on 'take our poll' - a yes/no response
--------------------------------------------------------------
Take Our Poll

Do you believe you developed chemobrain due to cancer and/or treatment?

Monday, October 04, 2010

Chemobrain ... Is It Real?



Cancer Newsline - 09/20/2010
Chemobrain, or difficulty in efficiently processing information, is a legitimate, diagnosable condition that may be caused by chemotherapy treatment, the cancer itself, or secondary medical conditions such as anemia. Christina Meyers, Ph.D., Professor of Neuro-Oncology at MD Anderson Cancer Center, discusses chemobrain and how it can affect cancer patients.

Guest(s): 
Christina Meyers, Ph.D.

Saturday, October 02, 2010

Memory Impairment Common in People with a History of Cancer « AACR News



"He calls the condition “cancer related cognitive dysfunction,” suggesting that it goes beyond the “chemobrain” label that has been attached primarily to women treated with chemotherapy for their breast cancer who reported problems in cognitive function (e.g., attention and memory). “These memory issues can be related to treatment, such as chemotherapy, radiation, and hormone therapies, or to the tumor biology itself, which could change brain chemistry and neurobehavioral function,” said Jean-Pierre."

Tuesday, September 07, 2010

NCI Cancer Bulletin: Chemotherapy Affects Brain Structure of Breast Cancer Patients - Chemobrain



Note: small study/also reference blog abstract posting



Chemotherapy Affects Brain Structure of Breast Cancer Patients
A new study has provided some of the strongest direct evidence to date that chemotherapy has physical effects on areas of the brain that, when altered, could be result in the array of cognitive symptoms that is often called “chemobrain.” The study was published online August 6 in Breast Cancer Research and Treatment.

In a small study of women with breast cancer, researchers from the Indiana University School of Medicine used MRI scans to show that chemotherapy was associated with a decrease in the density of brain gray matter. The affected areas include those involved in memory and in the ability to process information. Although several other studies have shown similar changes in these areas of the brain, this was the first study to follow women prospectively and to compare scans before and after chemotherapy.

“The alterations in gray matter density observed in the [chemotherapy] group are… consistent with the pattern of cognitive complaints and impairment found in neurocognitive studies,” wrote Dr. Andrew J. Saykin and colleagues.

The study included 17 women with breast cancer who underwent chemotherapy after surgery, 12 women with breast cancer who did not receive chemotherapy after surgery, and a control group of 18 healthy women. The initial MRI scans, performed shortly after surgery in the participants with cancer, showed no notable differences in gray matter density among the three groups. One month after completion of chemotherapy, however, MRI scans revealed notable decreases in gray matter density in women with breast cancer, as well as changes in gray matter density in women who received surgery only, although the changes for these women were not as great. No changes were seen in women in the control group. After 1 year, women treated with chemotherapy had recovered gray matter losses in some regions, but other deficits persisted.

Exactly how chemotherapy may be causing these changes is unclear, said study co-author Dr. Brenna McDonald. “However, the finding that the changes appear to resolve naturally to some degree in the first year after chemotherapy is completed is a very positive one,” she wrote in an e-mail message. Because of the limited follow-up in the study, she continued, it’s unclear how much further recovery may occur naturally. A number of studies have shown that such cognitive effects can persist for many years, she added. Additional studies are investigating whether other therapies, such as tamoxifen, may have similar effects on brain structure.

For more information on this topic, see: “Delving Into Possible Mechanisms for Chemobrain.”

Monday, August 30, 2010

abstract: Predictors of self-reported memory problems in patients with ovarian cancer who have received chemotherapy



Note: 'chemobrain'

Purpose/Objectives: To examine the association between self-report of memory problems and the most commonly reported concurrent symptoms by women with ovarian cancer who have received chemotherapy.
Findings: Nine symptoms accounted for 37% of the variance of memory problems (controlling for time since chemotherapy and education level). Significant predictors of memory problems included fatigue, mood swings, numbness or tingling, and sleep disturbance. Mean scores for self-reported memory problems were significantly different for participants who received chemotherapy compared to those who had not....cont'd